Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. - Wikidata - awgldk - TriplyDB

Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy.

Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy.

http://www.wikidata.org/entity/Q37248348

about

Degradation of the endothelial glycocalyx in clinical settings: searching for the sheddases The pathobiology of acute coronary syndromes: clinical implications and central role of the mitochondria Nanoparticle-Mediated Targeting of Cyclosporine A Enhances Cardioprotection Against Ischemia-Reperfusion Injury Through Inhibition of Mitochondrial Permeability Transition Pore Opening.Cardioprotection: Where to from here?Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction.Unique transcriptional profile of sustained ligand-activated preconditioning in pre- and post-ischemic myocardium.Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signaling Longitudinal peak strain detects a smaller risk area than visual assessment of wall motion in acute myocardial infarction.Long-term protection and mechanism of pacing-induced postconditioning in the heart.Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model Active Wnt signaling in response to cardiac injury.EphA2-receptor deficiency exacerbates myocardial infarction and reduces survival in hyperglycemic mice.Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations.Cardioprotective PKG-independent NO signaling at reperfusion Remote ischemic conditioning.Sustained ligand-activated preconditioning via δ-opioid receptors Influence of injectable hyaluronic acid hydrogel degradation behavior on infarction-induced ventricular remodeling MRI evaluation of injectable hyaluronic acid-based hydrogel therapy to limit ventricular remodeling after myocardial infarction.Targeted Delivery of VEGF after a Myocardial Infarction Reduces Collagen Deposition and Improves Cardiac Function.Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning.Protocol: does sodium nitrite administration reduce ischaemia-reperfusion injury in patients presenting with acute ST segment elevation myocardial infarction? Nitrites in acute myocardial infarction (NIAMI).Cardioprotection requires taking out the trash Macrophage depletion suppresses sympathetic hyperinnervation following myocardial infarction.Discordant signaling and autophagy response to fasting in hearts of obese mice: Implications for ischemia tolerance.The treatment of acute myocardial infarction: the Past, the Present, and the Future Mesenchymal stem cell transplantation for the infarcted heart: therapeutic potential for insulin resistance beyond the heart.Soluble epoxide hydrolase: a new target for cardioprotection Diminishing impairments in glucose uptake, mitochondrial content, and ADP-stimulated oxygen flux by mesenchymal stem cell therapy in the infarcted heart.Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.Myocardial remodeling, an overview.A role for GRK2 in myocardial ischemic injury: indicators of a potential future therapy and diagnostic.Is it time to translate ischemic preconditioning's mechanism of cardioprotection into clinical practice?Diabetic inhibition of preconditioning- and postconditioning-mediated myocardial protection against ischemia/reperfusion injury.Volatile anaesthetics and cardioprotection: lessons from animal studies.Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era.Surrogate and clinical outcomes following ischemic postconditioning during primary percutaneous coronary intervention of ST--segment elevation myocardial infarction: a meta-analysis of 15 randomized trials.Pharmacological attenuation of myocardial reperfusion injury in a closed-chest porcine model: a systematic review.Moving Forwards by Blocking Back-Flow: The Yin and Yang of MI Therapy.Remote ischaemic conditioning and remodelling following myocardial infarction: current evidence and future perspectives.

P2860

Q26828872-92C92580-6CEC-4E3A-B119-27FDC273D351 Q27026299-9723CA4A-8849-441B-99E6-99F0DBE0DB1F Q27350484-0B3C2AEE-5894-4A40-8EF3-740CCB14793C Q30244797-8BFA1046-D217-47B6-8307-18CA8A3A49F4 Q30279093-C99B2E21-21DB-4BDC-9444-B73486DAF3A9 Q31132643-536FA3AA-DA03-4812-AE18-548CABB3E1BF Q33552565-E74785A5-4494-4496-80A3-8C622984C02A Q33677751-3ABC6CA9-2604-479F-87A5-CF4F31688F57 Q33824028-B9186345-FD50-40AF-A717-9FB980A49CBA Q33953399-B79A50D1-384F-4EE8-9A1D-D641B1F4652B Q34044380-D3535D79-C093-4519-8220-A461B0E21B79 Q34100286-D3F8D224-689B-4686-A362-BA925B655326 Q34247485-9F71E23D-2DC8-464F-8589-3B8CBA3CC962 Q34426209-0EBEC5C4-3DA5-4FB7-B9A9-634C10FA6435 Q34458416-756B2A6C-ACF0-4A4F-B919-66DC8E6C091E Q34458657-89BCADD7-BE30-4115-9F44-76865F999B98 Q35634564-5383782A-C18F-4D3B-ADEF-D10C58DA67CE Q36016748-42E69D05-489F-455A-9C9E-C2BCAF392FA4 Q36119864-46F35C43-D4E3-4DA8-8A46-2C8AF806E2C2 Q36288965-31999B6D-402E-49EF-AAB5-DA04E7497CC4 Q36859185-6FBF976F-F276-4A54-B451-D443D1DFFA2B Q36867684-7B16AFD6-FA68-46A8-8CD5-54CEEF3247AE Q36954394-10073728-CF0E-47D4-96CA-B3E4781A1F6B Q37139586-010DE20B-6726-4B57-8DA1-3121ABCD8157 Q37140957-E86D3237-9955-4B75-9372-611D29DD0BD7 Q37357426-2BF61B85-E65B-424D-A4E1-CAD20772FEF0 Q37427615-6FFBC6B6-5E84-4556-87D1-BD4976E06D6B Q37575256-F3AA7A1F-D424-42E2-ABCA-B1FC6D4F4C95 Q37744271-4BE97CF8-E7EA-453A-852D-819772BCCA1E Q37792905-A2C0472C-30C8-4080-BC34-9D802DCD6A22 Q37907329-940071EF-9F9F-4D7E-BB93-BFAC12D07CBF Q37912841-E2B7F1DB-E1B6-47EA-8FC2-DB19231AEA12 Q37913053-A23BF409-67C6-49A8-A92D-63891B1588CC Q38026951-17779A7D-1DF5-46B1-B36B-B395FB449D64 Q38075417-9469D89E-5203-437E-B92A-23A77D6F2BE4 Q38199493-8E449A80-5A7F-4798-BB75-CFBD527E94EF Q38221826-05CBA10F-0FA8-46B6-B3B5-B136F7D6628D Q38227381-D89C973B-4E74-48E1-B5A7-6FAAFC1E54B5 Q38760245-5F530EDA-489A-4FFF-8D58-74D1655E1733 Q38833919-DA003F50-8165-40BE-A6C7-DB786F20A300

P2860

Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy.

http://www.wikidata.org/entity/Q37248348

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 August 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Limitation of myocardial infar ...... riments into clinical therapy.

@en

Limitation of myocardial infar ...... riments into clinical therapy.

@nl

type

label

Limitation of myocardial infar ...... riments into clinical therapy.

@en

Limitation of myocardial infar ...... riments into clinical therapy.

@nl

prefLabel

Limitation of myocardial infar ...... riments into clinical therapy.

@en

Limitation of myocardial infar ...... riments into clinical therapy.

@nl

P1433

Q37248348-AF47F8CF-B530-4A64-BC95-2B93AD32C6DE

P1476

Q37248348-2B81DC73-CB10-4172-9F5E-1F93AEF063DF

P2093

Q37248348-28E234ED-3A82-4D0E-9970-1B3079F3820F

Q37248348-8AE337C7-EDB9-4AD8-82B1-3F10DB6A0CAF

P2860

Q37248348-15EE549C-739A-457F-92C4-819D6D4D647E

Q37248348-49D3460A-6987-49C8-BA36-4C5E02C01B19

Q37248348-716403B5-2900-4CA6-AD32-9EC0E0506C96

Q37248348-7A21DA10-D9B9-4161-AE1B-395DC867D40D

Q37248348-DC80712F-D0AD-4890-AC88-12A0C463A146

Q37248348-F0329D31-AABC-4C5A-ADD3-3F8DD553F202

P2888

Q37248348-5591B99D-1DC7-4055-9CB9-99F0D025FE3A

P304

Q37248348-467A05DB-8ECF-4307-8640-3C7B8CE313AF

P31

Q37248348-4B426C55-64F1-40F8-8DA1-06F66F575E38

Q37248348-4aee9884-1a8b-4f6e-aba3-baa50dc23a11

P356

Q37248348-775442B7-09FD-407D-AF55-739C0E6F40D5

P433

Q37248348-38A3FD73-07A5-4F25-B90E-5CF5B025E26F

P478

Q37248348-DC856F3F-CDC3-4477-B7E9-D673D7046068

P577

Q37248348-EB4386B7-EBA3-40C8-82DD-0C72F96BDC3B

P698

Q37248348-50BFD0CC-9C66-4D71-9DEE-EBF327E1B58A

P356

S00395-008-0743-Y

P1433

Basic Research in Cardiology

P1476

Limitation of myocardial infar ...... riments into clinical therapy.

@en

P2093

Takayuki Miki

http://www.w3.org/2001/XMLSchema#string

Tetsuji Miura

http://www.w3.org/2001/XMLSchema#string

P2860

Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium

Determinants of infarct size in reperfusion therapy for acute myocardial infarction.

Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits.

Effects of balloon-based distal protection during primary percutaneous coronary intervention on early and late infarct size and left ventricular remodeling: a pilot study using serial contrast-enhanced magnetic resonance imaging.

Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models.

Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation.

P2888

s00395-008-0743-y

P304

501-513

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00395-008-0743-Y

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18716709

http://www.w3.org/2001/XMLSchema#string